Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Group 1 - Pfizer Inc. is set to release its Q1 earnings results on April 29, with expected earnings of 68 cents per share, a decrease from 82 cents per share in the same period last year [1] - The projected quarterly revenue for Pfizer is $14.09 billion, down from $14.88 billion a year earlier [1] - Guardant Health announced a strategic collaboration with Pfizer to enhance the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity smart liquid biopsy platform [2] Group 2 - UBS analyst Trung Huynh maintained a Neutral rating on Pfizer and reduced the price target from $28 to $24 [7] - Goldman Sachs analyst Asad Haider downgraded Pfizer from Buy to Neutral, cutting the price target from $32 to $25 [7] - Guggenheim analyst Vamil Divan reiterated a Buy rating for Pfizer, indicating a positive outlook [7]